InvestSMART

Percheron Therapeutics Limited (ASX: PER) - Share Price

- Current share price for PER : $0.004

Percheron Therapeutics Limited (PER, formerly Antisense Therapeutics Limited), an ASX-listed company, is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA.

PER General Information +

ASX Code PER
Website http://www.percherontx.com
Industry/Sector Pharmaceuticals
Market Cap ($M) 6
PER Share Price $0.004
Day High $0.004
Day Low $0.003
Last Close $0.004
PER Share Price Movement - ( No change )
Prices as at 16:40, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Percheron Therapeutics Limited (PER) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Percheron Therapeutics Limited (PER) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Percheron Therapeutics Limited (PER) price-sensitive announcements

PER - Quarterly Activities Report and Appendix 4C
Percheron Therapeutics Limited, a biotechnology company focused on novel therapies for onc
Percheron Therapeutics Limited (PER)
30 Apr 2026 | 8:57 AM
PER - Results of Entitlement Offer
Percheron Therapeutics Limited announced the completion of its Entitlement Offer, raising
Percheron Therapeutics Limited (PER)
14 Apr 2026 | 1:00 PM
PER - Prospectus - Non-renounceable Entitlement Offer
Percheron Therapeutics Limited's prospectus announces a non-renounceable entitlement offer
Percheron Therapeutics Limited (PER)
16 Mar 2026 | 10:01 AM
PER - Non-renounceable Entitlement Offer
Percheron Therapeutics Limited has announced a non-renounceable entitlement offer to raise
Percheron Therapeutics Limited (PER)
16 Mar 2026 | 9:59 AM

Percheron Therapeutics Limited (PER) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Percheron Therapeutics Limited (PER)
ORDINARY FULLY PAID
 Health Care $6 Completion of HMBD-002 Drug Substance Manufacture 17 Jun 2026 8:22AM $0.005 $0.004 fallen by 11.11%
Percheron Therapeutics Limited (PER)
ORDINARY FULLY PAID
 Health Care $6 New HMBD-002 Data Presented at ASCO Annual Meeting 2 Jun 2026 8:22AM $0.005 $0.004 fallen by 11.11%
Percheron Therapeutics Limited (PER)
ORDINARY FULLY PAID
 Health Care $6 Notification regarding unquoted securities - PER 1 Jun 2026 3:41PM $0.005 $0.004 fallen by 11.11%
Percheron Therapeutics Limited (PER)
ORDINARY FULLY PAID
 Health Care $6 Proposed issue of securities - PER 29 May 2026 11:26AM $0.005 $0.004 fallen by 11.11%
Percheron Therapeutics Limited (PER)
ORDINARY FULLY PAID
 Health Care $6 WHO selects proposed INN for HMBD-002 26 May 2026 9:22AM $0.005 $0.004 fallen by 11.11%
Percheron Therapeutics Limited (PER)
ORDINARY FULLY PAID
 Health Care $6 Notification of cessation of securities - PER 1 May 2026 8:15AM $0.005 $0.004 fallen by 11.11%

PER Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$14.92 -$1.40 7.80% 0.00 0.00 0.00% 0.0%
2024A -$11.92 -$1.30 -20.40% 0.00 0.00 0.00% 0.0%
2023A -$11.38 -$1.60 86.20% 0.00 0.00 0.00% 0.0%

PER Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Clarity Pharmaceuticals Ltd (CU6) $761M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $1,618M -0.7857 0.0743 1.2000 54.8346 51.0400 23.2000 0.00% 0.00% 0.00%
Percheron Therapeutics Limited (PER) $6M 0.0775 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

PER Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 0.45 0.00
Market 0.29 13.30 1.15 0.66
Sector 0.42 26.20 2.41 2.34

PER Directors

Name Position Start Date
Dr James Garner Chief Executive Officer, Managing Director 8 May 2023
Dr Charmaine Hilary Gittleson Executive Chairman, Executive Director 22 Mar 2021
Dr Ben Gil Price Non-Executive Director 4 Oct 2021

Percheron Therapeutics Limited (PER) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
15 Apr 2026 GARNER, James Issued Direct Shares 21,400,000 $0.005 $107,000.000
22 Dec 2025 PRICE, Ben Buy Direct Shares 2,000,000 $0.009 $17,220.060
19 Dec 2025 GARNER, James Buy Direct Shares 1,000,000 $0.009 $8,500.000

See all changes in directors' interest & trades for Percheron Therapeutics Limited (PER) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PER Management

Name Position
Deborah Ambrosini Chief Financial Officer,Company Secretary

PER Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Percheron Therapeutics Limited (PER). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
59,199,300 (5.44%) Mutual Investments Pty Ltd

PER Calendar of Events

Date Event
25 February 2027 Report (Interim)
27 August 2026 Report (Annual)
27 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.